Halozyme Therapeutics, Inc. (HALO) said argenx received approval from Japan's Ministry of Health, Labour and Welfare for VYVDURA injection co-formulated with Halozyme's ENHANZE drug delivery technology for subcutaneous use for the treatment of adult patients with generalized myasthenia gravis, who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.
Sekisui House, Ltd., and M.D.C. Holdings, Inc. (MDC) announced a definitive agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.
A report released by the Federal Reserve Bank of Philadelphia on Thursday showed regional manufacturing activity contracted at a slightly slower rate in the month of January.
Stock of BridgeBio Pharma, Inc. (BBIO) gained 4 percent on Thursday after the company announced that it will receive strategic financing of up to $1.25 billion from Blue Owl Capital and Canada Pension Plan Investment Board, a subsidiary of CPPIB Credit Investments Inc.
The Labor Department released a report on Thursday showing an unexpected decrease in first-time claims for U.S. unemployment benefits in the week ended January 13th.